LILRB4 and melanoma: Studies have shown that the immunosuppressive capacity of MDSCs is adjusted by the inhibitory molecule leukocyte immunoglobulin-like receptor B4 (LILRB4) in patients with non-small-cell lung cancer and in mice with melanoma occurring as subcutaneous tumors [21, 22].